For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
6
views
23
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      6,472
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Andexanet alfa — Recommendations for clinical use. Multidisciplinary experts’ standpoint

      discussion

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

          Stuart Connolly, Mark Crowther, John W Eikelboom … (2019)
          Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors.
          Article 0 comments Cited 235 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.

            Jerrold Levy, Charles V Pollack, Paul Reilly … (2017)
            Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran.
            Article 0 comments Cited 234 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

              Deborah Siegal, John T Curnutte, Stuart Connolly … (2015)
              Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. Andexanet is designed to reverse the anticoagulant effects of factor Xa inhibitors.
              Article 0 comments Cited 82 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Cardiol J
                Journal ID (iso-abbrev): Cardiol J
                Title: Cardiology Journal
                Publisher: Via Medica
                ISSN (Print): 1897-5593
                ISSN (Electronic): 1898-018X
                Publication date Collection: 2023
                Publication date (Electronic): 31 August 2023
                Volume: 30
                Issue: 4
                Pages: 502-505
                Affiliations
                [1 ]Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
                [2 ]Gajda-Med Medical Center, Pultusk, Poland
                [3 ]3 rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
                [4 ]Department of Cardiology, Institute of Medical Sciences, University of Opole, Poland
                [5 ]Mossakowski Medical Research Institute, Polish Academy of Science, Warsaw, Poland
                [6 ]1 st Department of Cardiology, Medical University of Gdansk, Poland
                [7 ]Department of Cardiac Rehabilitation and Health Promotion, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
                [8 ]Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland
                [9 ]Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Poland
                [10 ]Department of Emergency Medicine, Medical University of Bialystok, Poland
                [11 ]Department of Cardiology, Medical University of Bialystok, Poland
                Author notes
                Address for correspondence: Prof. Jacek Kubica, Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, ul. M. Skłodowskiej-Curie 9, 85–094 Bydgoszcz, Poland, e-mail: jkubica@ 123456cm.umk.pl
                Author information
                https://orcid.org/0000-0001-8250-754X
                https://orcid.org/0000-0001-9719-0987
                https://orcid.org/0000-0002-4608-0881
                Article
                Publisher ID: cardj-30-4-502
                DOI: 10.5603/CJ.a2023.0043
                PMC ID: 10508081
                PubMed ID: 37401419
                SO-VID: b0428ea2-8314-4b24-aefd-fbe379bf00fc
                Copyright © Copyright © 2023 Via Medica
                License:

                This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially

                History
                Date received : 23 May 2023
                Date accepted : 15 June 2023
                Categories
                Subject: Clinical Cardiology
                Subject: Experts’ Viewpoint

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content6,472

                See all similar

                Cited by1

                See all cited by

                Most referenced authors366

                See all reference authors